glp-1 market forecast Obesity North America Glucagon-Like Peptide-1 (GLP-1)

Lilly receives U.S

So this is a growing threat that I think needs to be monitored closely. If GLP-1s do become prohibited, athletes could theoretically apply for a therapeutic use exemption (TUE), which allows them to take a drug if it is treating a legitimate medical condition, and does not meaningfully enhance their performance

Trend summaries from EU authorities and FDA Form 483 data consistently show that contamination-related deficiencies account for a substantial share of the critical and major GMP findings in sterile operations year after year, and recent recall reviews have repeatedly traced sterility-assurance failures and environmental-control breakdowns as leading root causes even at organisations with otherwise mature quality systems

Your Next Steps Neither medication is magic